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ABSTRACT
Dose uniformity is a key quality element of drugs. The purpose of this study was to demonstrate a practical approach to evaluate
the breakability robustness as part of the tabletting validation of a scored tablet. The influence of operational compression parameters
(speed and force) on the weight variabilities of half- and quarter-tablets was investigated using two types of cross-scored round tablets
of identical composition but different in size. It was shown for the used veterinary model tablet that manufacturing variation of two
compression parameters around the defined target values do not significantly influence the weight variability of the broken tablets. The
empirical guidance was also confirmed that for the investigated dose-proportional tablets the standard deviation of the broken tabletpart weight is linearly related to the original tablet weight. There exists a strong correlation between the variability of half-tablets and
of quarter-tablets: the theoretical model previously presented was refined, demonstrating that the additional variance induced by
breaking is a linear function of the break-line length. As a consequence, the standard deviation of half- and quarter-parts of crossscored round tablets, expressed in mass units, will thus remain approximately identical. Hence, the relative standard deviation (RSD) of
quarter-tablet weights will nearly double when breaking half-tablets into quarter-tablets.
Key words: scored tablets, tablet breakability, weight uniformity, statistical control, compression validation, robustness development

INTRODUCTION
Tablets with single or multiple score lines allow the
administration of a portion of the tablet, which can then be
considered as the unit dosage of the drug. Pharmacopoeial
and other regulatory documents acknowledge this, e.g. the
EP monograph Tablets(1) clearly defines that tablets may
have breakmarks. In the production section of the current
EP monograph (not in the testsection), it is explicitly stated
that for tablets for which a subdivision is authorized, it
must be demonstrated to the satisfaction of the competent
authority that the subdivided parts comply either with
content-uniformity (test A of EP 2.9.6.) or mass-uniformity
(EP 2.9.5.) as appropriate. From this definition, it is clear
that uniformity of tablet portion after breaking or splitting
is certainly a quality attribute of the tablet, although it may
not be considered as a regulatory obligatory routine QC test
much the same as with microbiological purity. Both
examples relate to the concept of parametric release. This
is confirmed by the recent proposal (2), stating that the
breakability has to be assessed during development using
mass-uniformity criteria. In the development pharmaceutics guidance CPMP/QWP/155/96(3), the general regulatory
opinion of the authorities is expressed, stating that the
* Author for correspondence.
E-mail: Bart.DeSpiegeleer@UGent.be

practice of administration of half-tablets should be discouraged. However, the same sentence also says that where
such an approach has been justified in the application,
which can be based upon posology or ease of intake considerations(2), it is important to demonstrate the maintenance
of dosage uniformity within tablet halves by breakability
tests. The EC-Variations (4) demonstrates the abundant
practice by the industry and careful acceptance by the
authorities of the use of broken tablet-parts, where in the
case of a change in tablet dimension (type I variation,
number 40), breakability data at release as well as at endof-shelf-life are ultimately required. Examples of the
current general regulatory decisions are found in the scientific EPAR discussions of the EMEA, e.g. CPMP/5346/02(5)
or CVMP/265/00(6).
In the US, scoring is being addressed in several FDA
documents, e.g. MAPP5223.2 Scoring configuration of
generic drug products(7). The uniformity of dosage units
(USP/NF 905) described in the USP/NF(8) is in general
based on the weight combined with the assay of 10 dosage
units. If only the weights of units are considered, compliance sensu strictu with the USP requirements cannot be
demonstrated as such. However, if consistent content
homogeneity has been demonstrated by the validation
results, the weight is considered a valid dose-uniformity
quality attribute.
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The regulatory interest was fuelled by an increasing
number of researches and discussion papers. Previous
papers often gave the breakability results and recommendations from a general pharmaco-therapeutic practical point of
view(9-10), while developmental, manufacturing and quality
technical aspects were seldomly discussed(11-16). To our
knowledge, the robustness of breakability variability as part
of the manufacturing process characterization has not yet
been studied and reported. Certain research documents
discuss a number of alternative acceptance criteria (17-18),
generally allowing relative mass variations of broken
tablets to be higher than that of intact tablets.
In addition to the technical aspects, pharmacoeconomic, in-use and clinical considerations such as
posology regimen, therapeutic window, pharmaco-kinetics
and related PK/PD-relations have to be taken into account
to justify the existence of a breaking line and to qualify the
applied breakability acceptance criteria with the regulatorypharmacopoeial texts as general guidelines(19-21).
A previous paper (22) investigated the influence of
breakability methodology on mass uniformity of half- and
quarter-tablets, as well as different data acquisition, evaluation and criteria-approaches, using a discriminative model
tablet.
As part of the manufacturing development, the aim of
this study was to investigate the influence of operational
compression parameters during tabletting on the weight
variabilities of half- and quarter-tablets, as well as to
compare variously sized tablets of identical composition.
This study provided a practical example of robustness-verification.

MATERIALS AND METHODS
I. Drug Dosage Form Tested
Two types of tablets having identical composition and
originating from the same granulate were used in this study.
The tablets differed in size (400 mg tablet versus 1000 mg
tablet). All tablets were flat and cross-scored on one side,
and contained 22% m/m drug substance. The tablets were
for veterinary use in the treatment of dogs: the large weight
variety in the target animal species justified the requirement
of a cross-scored tablet for the intended purpose.
The tablets were manufactured by typical wet granulation process using a fluidized bed granulator (Glatt
WSG120) followed by powder blending in a conical
blender and compression performed with a rotary tablet
press equipped with 32 stations (Kilian RTS32). The
tablets consisted of microcrystalline cellulose, sorbitol and
dried yeast lysate as main excipients. It was previously
shown that this tablet was suitable as a discriminative
model tablet relative to breakability(22).
The ranges of operational compression settings for
manufacturing the 400 mg and 1000 mg tablets were
chosen for a manufacturing robustness assessment valida-

tion of the compression stage. Therefore, the ranges were
as wide as practically possible around the operational
target-values with the available compression equipment.
The compression speed for the 400 mg tablet varied
between 50 and 90 thousand tablets per hour, whereas for
the 1000 mg tablet it varied between 40 and 70 thousand
tablets per hour. The compression force was manually
adjusted, with the maximum at 40 kN for the used punches.
Force settings were ranked on the equipment as high,
medium and low. Tablet hardness was determined as the
force required to break the tablet in a diametral compression test (i.e. the tablet crushing strength), using a
PharmaTest equipment (type PTB301).
All tested tablets were flat and round, with 11 mm
(400 mg tablet) and 15 mm (1000 mg tablets) diameters.
The score lines applied in these cross-scored tablets had the
following specifications(23):
1. 400 mg tablets: W (width) = 0.88 mm, D (depth) =
0.42 mm, θ = 45˚ and R (engraving cut radius) =
0.05 mm.
2. 1000 mg tablets: W = 1.20 mm, D = 0.58 mm, θ =
45˚ and R = 0.05 mm.
II. Breakability Test Method
The following breakability test method was applied in
this robustness study by the manufacturing operators: hold
the tablet between the thumb and index-finger of each hand
on either side of the score line, with the score line facing
upwards and without inserting the nail. Separate into two
halves by a rotating movement at the joint of the first two
phalanges of the index-fingers.
To validate the used breakability test method, a
slightly alternative breakability test method was also
applied on the 400 mg tablet compressed under medium
speed and force in more controlled laboratory conditions by
three persons, giving similar results (see Results and
Discussion section): The two halves were separated by
breaking open the tablet at the score line side.
The methods described above are applicable to break
the tablets into half-tablets, as well as to break half-tablets
into quarter-tablets.
III. Data Acquisition
The previously described protocol (22) contains all
possible weight information and allows detailed investigations of all possible relationships such as left-right differences, half-to-quarter interactions. However, this protocol
is not feasible and justified for routine validation purposes.
For the data evaluation currently used, only one half-tablet
is retained per tablet, taken alternatively from the right and
left hands. Similarly, only one quarter-tablet is retained per
tablet, taken alternatively from each of the 4 possible
quadrants.
Breakability losses obtained from breaking tablets into
half-tablets and into quarter-tablets had been investigat-
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ed(22). A mean loss per tablet of 0.3% was obtained in
previous study with the applied breaking methods. Hence,
for practical purposes, the losses were not measured nor
included in the currently reported results.
The calculation of tensile strength σt (N•mm-2 or MPa)
for these flat-faced tablets was determined from the mean
force value F (N) at which the tablet fractured under
diametral compression (hardness value), according to the
following equation σt = 2F/ (πDt), where D is the tablet
diameter (mm) and t is the overall tablet thickness (mm)(24).
As the score-depth is only 0.42 mm for the 400 mg tablets
and 0.58 mm for the 1000 mg tablets, we have again
neglected this small deviation for practical reasons, and
used the thickness of the whole tablet as t value in the
tensile strength equation.
IV. Data Analysis
Excel was used for data preparation and processing.
Statistical analyses were performed with SPSS 9.0. For all

statistical tests, a critical significance level α = 0.05 was
chosen.
Graphical exploration of the data was performed i.a.
by boxplots, visualizing the median, the 25th and 75th percentile (Tukey’s hinges between which 50% of the values
are located), and the smallest and largest values that aren’t
outliers. The outliers are individually represented in the
figures, classified as the values differing more than 1.5 boxlengths from the 75th percentile (denoted as o in the
Figures) and the values differing more than 3 box-lengths
from 75th percentile (denoted as * in the Figures).

RESULTS AND DISCUSSION
Figures 1 and 2 present summarizing boxplots with the
weights of half- and quarter-tablets for each of the tested
operational compression settings from 1000 mg and 400 mg
tablets respectively. Further, a tabular overview of the corresponding data (mean and standard deviation), tablet
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Figure 1. Boxplots with weights (mg) of half- and quarter-tablets from 1000 mg tablets of three operational compression speed and force
settings (n = 20 per operational setting).
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Figure 2. Boxplots with weights (mg) of half- and quarter-tablets from 400 mg tablets of three operational compression speed and force settings
(n = 20 per operational setting).
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Table 1. Effect of operational compression conditions (speed and force) on tablet characteristics
Test tablet
Compression Compression
Weight (mg) (mean ± S.D.) (n = 20)
forceb
speeda
Whole tablets
Half tablets
Quarter tablets

Hardness (N)
Mean
(mean ± S.D.)
thickness
(n = 10) (tensile
(mm)
strength in MPa)
(n = 10)
400 mg tablet
Medium
Medium
400.1 ± 2.6
200.9 ± 15.5
98.2 ± 13.9
71.2 ± 2.8 (1.12)
3.68
Low
Medium
402.8 ± 2.8
195.0 ± 30.0
105.2 ± 20.0
71.1 ± 2.5 (1.12)
3.69
High
Medium
397.9 ± 3.3
203.0 ± 27.6
91.5 ± 18.6
68.6 ± 3.3 (1.07)
3.70
Medium
Low
396.8 ± 3.3
197.8 ± 9.3
98.2 ± 7.3
47.4 ± 2.1 (0.71)
3.85
Medium
High
399.3 ± 3.4
201.4 ± 18.5
101.9 ± 11.1
86.0 ± 3.2 (1.40)
3.56
399.4 ± 3.1
199.6 ± 20.2
99.0 ± 14.2
68.9 ± 2.8 (1.08)
3.70
Overallc
249.6 ± 49.9
120.2 ± 5.5 (1.01)
5.07
1000 mg tablet
Medium
Medium
1005.6 ± 6.3
509.4 ± 81.0d
Low
Medium
999.2 ± 6.9
496.7 ± 54.6
242.6 ± 32.5
116.7 ± 5.6 (0.979)
5.06
High
Medium
991.5 ± 8.5
529.7 ± 54.6
232.9 ± 46.8
113.0 ± 3.8 (0.950)
5.05
243.1 ± 54.9
77.3 ± 4.6 (0.614)
5.35
Medium
Low
1000.7 ± 6.6
513.3 ± 96.5d
Medium
High
1003.9 ± 7.2
521.1 ± 41.7
239.8 ± 37.9
131.1 ± 5.2 (1.11)
5.03
Overallc
1000.2 ± 7.1
514.0 ± 65.7
241.6 ± 44.4
111.7 ± 5.0 (0.928)
5.11
a
For the 400 mg tablets: low, medium (= standard setting) and high speed are 50, 70 and 90 thousand tablets/hr, respectively.
For the 1000 mg tablets: low, medium (= standard setting) and high speed are 40, 50 and 70 thousand tablets/hr, respectively.
b
Arbitrary setting on used compression equipment.
c
Mean of all values.
d
This high standard deviation results from the fact that the obtained breaking line does not coincide with the score-line: at least one half-tablet
weight was deviating more than 30% of the target weight.

weight, hardness and thickness data are given in Table 1.
Looking at the breakability results, with much higher
variabilities than the pharmacopoeial criteria which in its
most general form requires a relative standard deviation of
below 6.0% for n = 20 tablets (1,2,8,22), it must be emphasized that the investigated tablets are for veterinary
purposes only and that they are presented with only a onesided break-line, which contrasts the human tablet situation
where quite often, double-sided break-lines are applied.
The relationships between the observed variabilities in
tablet, half-tablet and quarter-tablet weights (expressed as
standard deviations) on the one hand, and the tablet related
characteristics hardness and thickness on the other hand can
be visualized with a scatterplot matrix in Figure 3.
From this scatterplot matrix, little relationship was
observed between hardness or thickness and the individual
standard deviations. However, there did appear to be a
relationship between the standard deviations of half- and
quarter-tablets.
Seen the fractional experimental design, the effects of
the investigated factors within each tablet group were independently analyzed using one-way ANOVA models with 3
factor levels within each factor (i.e. no interactions studied).
Within the 400 mg tablet group, the effect of compression
speed and force on the half-or quarter-tablet weights was
not statistically significant. Similar conclusions are
obtained within the 1000 mg tablet group. Excluding the
outliers (see footnote under the tables), the same statistical
conclusions were obtained in the 1000 mg tablet group.
The homogeneity of variance, a basic assumption for
ANOVA, was confirmed for each of the ANOVA models
using the Levene’s test(26). The results showed that the
compression speed and force did not have a significant
effect on the weights of the broken tablets. It was thus
concluded that this manufacturing step is sufficiently robust

Std dev 1

Std dev
1/2

Std dev
1/4

Hardness

Thickness Test
400 mg
1000 mg

Figure 3. Scatterplot matrix of tablet characteristics.

to produce tablets with consistent breakability characteristics, leading to reproducible mass uniformity of broken
tablets. Particle characteristics such as particle size distribution and powder flowability, which can affect the packing
behaviour during compression and influence mass uniformity phenomena, were not part of this study on the operational tabletting stage.
Table 1 demonstrates that the tablet hardness and thickness are related to the compression settings. Using one-way
ANOVA analysis followed by the Duncan test for multiple
comparisons of means, it was experimentally concluded that
unlike the compression force, the compression speed within
the current operational settings had no significant effect on
the hardness of the investigated tablets. Our observation on
constant mass per tablet for the different compression set-
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tings showed that the effect on hardness was inversely
related to the thickness of the tablets (see Figure 3).
Although in general, the lower the compression speed, the
longer the contact time leading to increasing tablet strength,
our results are constrained within certain operational conditions and are aimed at the evaluation of manufacturing
robustness of partial tablets uniformity. In addition, the
tablet friability was also investigated according to the
European Pharmacopoeia (data not shown) and found to be
between 0.0% and 0.2%. No observable effects of the
investigated compression settings on the friability were
observed. The hardness of tablets is more sensitive than the
breakability variability towards the operational compression
speed and force settings, confirming the usefulness of this
measurement for in-process compression control.
The calculated tensile strengths for the investigated
tablets ranged between 0.614 and 1.40 MPa. No direct
relationship could be observed between the breakability
standard deviation and the calculated tensile strength σt.
However, since this conclusion is sensu strictu only valid
for the investigated tablets and the crushing, diametrical
hardness test method, using other tablets or even changing
the test method, e.g. knife-edge cutting or three-point
bending test, could lead to other conclusions.
From the data presented here, tablet and partial tablet
weight variability in function of tablet size (400 mg versus
1000 mg) and the specific relationship between half-tablet
and quarter-tablet variabilities for these 2 tablets are further
investigated.
The 400 mg tablets, compressed with medium speed
and force settings, were broken into half-tablets and
quarter-tablets using an alternative, more controlled method
in the laboratory. The tablet and broken-tablet variabilities
obtained from both test-methods were statistically
compared with F-tests. Two-sided significance levels p =
0.18 and p = 0.32 were obtained for half-tablets and
quarter-tablets comparison respectively, confirming the similarity between the two breakability test methods.
It was observed that the whole tablet, half-tablet and
quarter-tablet weight variability (expressed as standard
deviation) decreased with decreasing tablet size (see Table
1). More specifically, the ratio of both tablet weights was

2.5 (1000.2 mg versus 399.4 mg), whereas the corresponding ratios of the standard deviations of whole tablet, halftablet and quarter-tablet weights (together with their 99%
confidence interval) were respectively 2.3 (1.8 - 3.0), 3.3
(2.5 - 4.3) and 3.1 (2.4 - 4.1) (see overall values in Table 1).
This result indicated that the tablet and part-of-tablet weight
variability (expressed as standard deviation) was a linear
function of tablet weight for the currently investigated
model tablets. This was in correspondence with the results
obtained in a similar study(21) with a palatable bisected
tablet: the half-weight variability was found to be 51 mg
(17%RSD), 84 mg (11%RSD) and 204 mg (13%RSD) for
the half-tablets of 600 mg (mean half-weight = 299.7 mg),
1500 mg (mean half-weight = 757 mg) and 3000 mg (mean
half-weight = 1529 mg) tablets of identical shape. The
breakability variability of the currently investigated doseproportional tablets is thus a peculiar case of heteroscedasticity with constant relative standard deviation(25). It is to
be pointed out that a strict theoretical and universally
applicable comparison of the two tablet sizes can in
principle be confounded with the speed-factor, as both were
simultaneously different in this study. However, from the
presented data, it appears that the relation of the breakability variability with the tablet mass for dose-proportional
tablets is a useful empirical first estimation.
The relationship between the half-tablet variability and
quarter-tablet variability within one tablettype was further
investigated by calculating the ratio of standard deviation of
quarter-tablets to the standard deviation of half-tablets. A
95% confidence interval was constructed using an F-distribution. The results are tabulated in Table 2.
A previous paper(22) hypothesized that the variability
of partial tablets (expressed as variance) within one tablet is
a linear function of the length of the score (i.e. the longer
the score, the higher the variability of the corresponding
partial tablet’s weight). Based on this hypothesis and disregarding the whole tablet variability, it was deduced that the
theoretical expected ratio of quarter-tablet to half-tablet
variability is 0.87. The experimental results (see last
column in Table 2) are in-line with this theoretical value.
In general, the following mathematical model is
applicable: If the variabilities of tablets, half-tablets and

Table 2. Weight variabilities related to breaking tablets into half-tablets and half-tablets into quarter-tablets (expressed as standard deviations)
and ratio (with 95% confidence interval) of s1/4 to s1/2 for two different test tablets and various compression conditions
Test tablet
Compression speed
Compression force
s1
s1/2
s1/4
sB1
sB2
Ratio s1/4 to s1/2
400 mg tablets
Medium
Medium
2.6
15.5
13.9
15.4
11.5
0.90 (0.56, 1.43)
Low
Medium
2.8
30.0
20.0
30.0
13.2
0.67 (0.42, 1.06)
High
Medium
3.3
27.6
18.6
27.6
12.5
0.67 (0.42, 1.07)
Medium
Low
3.3
9.3
7.3
9.2
5.6
0.78 (0.49, 1.25)
Medium
High
3.4
18.5
11.1
18.4
6.1
0.60 (0.38, 0.95)
49.9
80.9
29.2
0.62 (0.39, 0.98)
1000 mg tablet
Medium
Medium
6.3
81.0a
Low
Medium
6.9
54.6
32.5
54.5
17.6
0.60 (0.37, 0.95)
High
Medium
8.5
54.6
46.8
54.4
38.0
0.86 (0.54, 0.95)
54.9
96.4
26.2
0.57 (0.36, 0.90)
Medium
Low
6.6
96.5a
Medium
High
7.2
41.7
37.9
41.5
31.6
0.91 (0.57, 1.44)
a
This high standard deviation results from the fact that the obtained breaking line does not coincide with the score-line: at least one half-tablet
weight was deviating more than 30% of the target weight.
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60

quarter-tablets are respectively called s12 , s12/ 2 and s12/ 4 , then
the following mathematical relationships exist:
s
+ sB21 ......................................................................(1)
4

s12/ 2
s2 s2
+ sB2 2 = 1 + B1 + sB2 2 ..........................................(2)
4
16 4
2
s : Intrinsic variability of half-tablets inherited
With 1
from whole tablets
4
s12/ 4 =

2
: Additional variability due to breaking a whole
sB1
tablet into half-tablets

s12/ 2 : Intrinsic variability of quarter-tablets inherited
4 from halves.
2
: Additional variability due to breaking a halfsB2
tablet into quarter-tablets.
2
2
The variabilities sB1 and sB2
induced by the breaking
process can be calculated from equation (1) and (2) and the
experimentally determined variances s12 , s12/ 2 and s12/ 4 . An
overview of the above mentioned variability components is
given in Table 2.
Under the hypothesis that the variability of partial
tablets (expressed as variance) is a linear function of the
length of the score, the following relationship for a crossscored round tablet is valid:

sB2 2 =

1 2
sB1 or sB2 = 0.71 × sB1 ..............................................(3)
2

In two particular cases (indicated in footnote a in Table
2), individual half-tablets weights were more than 30%
different from the theoretical values due to irregular tablet
breaking, in which the breaking line did not coincide with
the score line. This off-score breaking behavior is beyond
the scope of the theoretical hypothesis (see equation 3) and
therefore these two cases are excluded from the linear
regression model. Additional not reported data obtained
with the alternative breakability method were also included
in the linear regression model. The resulting experimental
correlation between sB1 and sB2 is visualized in Figure 4,
and the corresponding regression equation is (95% confidence intervals between brackets):
sB 2 = 4.3 ( −4.6 to 13.2) + 0.51 (0.21 to 0.80) sB1 ................(4)

Therefore, the hypothesis that the variability of partial
tablets (expressed as variance) is a linear function of the
score length is confirmed by the available data.
Consequently, it may be concluded that the variability
of broken tablets is mainly determined by the half-tablet
variability, and that breaking half-tablets into quarter-tablets
does not imply increase in variability. However, if relative
standard deviations are considered, the RSD of quartertablets is approximately twice the variability of half-tablets.
Moreover, this finding may also have consequences for the
final choice of the form of the tablet: unlike a round tablet,

R2 = 0.47

50

Standard deviation B2

s12/ 2 =

2
1
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Figure 4. Scatterplot illustrating the correlation between the variability due to breaking tablets into half-tablets (B1) versus the variability
due to breaking half-tablets into quarter-tablets (B2). Both variabilities are expressed as standard deviation.

will an oblong tablet have smaller and constant length of
score.
While this study focused only at the operational tabletting robustness, there are still numerous remaining issues.
A global mechanistic model is one of the ultimate goals yet
awaiting further exploration. This model will need to
consider additional factors like score line characteristics,
particle properties such as particle size and size distribution
and its densification packing behavior, bonding mechanisms of plastic deformation, brittle fragmentation, and
relaxation phenomena. Moreover, the criteria are still a
matter of discussion (for example reference 27), but should
ultimately reflect a risk assessment specific for the tabletted
drug under consideration.

CONCLUSIONS
The purpose of this investigation, as part of a case
study of a tablet manufacturing validation, was to study the
influence of the operational tabletting parameters (speed
and force, and resulting physical tablet characteristics) on
the weight variability of half- and quarter- tablets. The
secondary purpose was to determine the possible relationship between the variabilities of the half-tablets and the
quarter-tablets.
Using 400 mg and 1000 mg discriminative flat model
tablets, we have demonstrated that variation of the compression speed and force around their target values does not
significantly influence the weight variability of half- and
quarter-tablets. Moreover, it was observed that tablet
hardness is more sensitive towards the operational tabletting speed and force, confirming the discriminative power
and thus possible usefulness of this physical parameter for
in-process compression control.
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The breakability methodology was cross-validated: a
highly controlled test method executed in the laboratory,
gave similar results as the applied method executed in an
in-process situation at the tablet manufacturing plant.
In correspondence with other breakability studies, it
was confirmed that for tablets with identical composition
but different in size, the standard deviation of whole and
partial tablet weights is linearly related to the tablet weight.
There exists a strong correlation between the variability of half-tablets and that of quarter-tablets. The theoretical
model presented in a previous paper was further refined and
verified with the current data, and it was confirmed that the
additional variance induced by breaking is a linear function
of the break-line length. As a consequence, the standard
deviation of half- and quarter-tablets, expressed in mass
units, will thus remain approximately identical for round
tablets, and hence the relative standard deviation (RSD) of
quarter-tablet weights will always be higher when breaking
half-tablets into quarter-tablets.
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